HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
ASCO-SITC Clinical Immuno-Oncology Symposium 2019 Poster of Rivoceranib AM107 Study
This poster was presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco, California on Feb 28, 2019. It presents the preliminary results of a Phase I study evaluating safety and efficacy of rivoceranib and nivolumab in patents with unresectable or metastatic cancer. Preliminary results indicate the potential clinical benefit of rivoceranib and nivolumab combination therapy in unresectable/metastatic solid tumors with a tolerable safety profile.